Abstract:Background Evidence is limited regarding the association of circulating metabolites with decline of kidney function, letting alone their value in prediction of development of chronic kidney disease (CKD). Methods This study included 3802 participants aged 64.1 ± 7.4 years from the Dongfeng-Tongji cohort, among whom 3327 were CKD-free at baseline (estimated glomerular filtration rate [eGFR] > 60 ml/min per 1.73 m2). We measured baseline levels of 211 metabolites with liquid chromatography coupled with mass spectrometry, including 25 amino acids, 12 acyl-carnitines, 161 lipids, and 13 other metabolites. Results The mean (SD) absolute annual change in eGFR was −0.14 ± 4.11 ml/min per 1.73 m2 per year, and a total of 472 participants who were free of CKD at baseline developed incident CKD during follow-up of 4.6 ± 0.2 years (14.2 %). We identified a total of 22 metabolites associated with annual eGFR change and survived Bonferroni correction for multiple testing, including seven metabolites associated with eGFR increase (six being docosahexaenoic acid [DHA]-containing lipids) and 15 associated with eGFR decline (nine being phosphatidylcholines [PCs]). Among them, eight metabolites obtained non-zero coefficients in least absolute shrinkage and selection operator (LASSO) regression on incident CKD, indicating predictive potential, including one amino acid (arginine), one acyl-carnitine (C2), one lysophosphatidylcholine (LPC 22:6), two PCs (32:1 and 34:3), one triacylglycerol (TAG 56:8 [22:6]) and two other metabolites (inosine, niacinamide), and the composite score of these eight metabolites showed an odds ratio (OR) of 8.79 (95 % confidence interval [CI]: 7.49, 10.32; P < 0.001) per SD increase in association with incident CKD. The addition of the metabolite score increased the c-statistic of the reference model of traditional risk factors (including baseline eGFR) by 0.065 (95 % CI: 0.046 to 0.084; P = 3.39 × 10−11) to 0.765 (0.742 to 0.788) in 1000 repetitions of 10-fold cross-validation, while the application of two advanced machine learning algorithms, random forest (RF), and extreme gradient boosting (XGBoost) models produced similar c-statistics, to 0.753 (0.729 to 0.777) and 0.778 (0.733 to 0.824) with increases of 0.074 (0.055 to 0.093; P = 4.11 × 10−14) and 0.073 (0.032 to 0.114; P = 4.00 × 10−4), respectively. Conclusions In this study, we identified 22 metabolites associated with longitudinal eGFR change, nine of which were PCs and six were DHA-containing lipids. We screened out a panel of eight metabolites which improved prediction for the development of CKD by 9 % beyond traditional risk factors including baseline eGFR. Our findings highlighted involvement of lipid metabolism in kidney function impairment, and provided novel predictors for CKD risk.

Lipid parameters, adipose tissue distribution and prognosis prediction in chronic kidney Disease patients

Predicting Cardiovascular Mortality in Chronic Kidney Disease (CKD) Patients.

The association between dyslipidemia and the incidence of chronic kidney disease in the general Zhejiang population: a retrospective study

Lipid Parameters and the Development of Chronic Kidney Disease: A Prospective Cohort Study in Middle-Aged and Elderly Chinese Individuals

Association of Lipid Parameters with the Risk of Chronic Kidney Disease: A Longitudinal Study Based on Populations in Southern China

Body composition as a potential imaging biomarker for predicting the progression risk of chronic kidney disease

The Association between Baseline Serum Lipids and Mortality in Peritoneal Dialysis Patients

Clinical study of hyperlipidemia and chronic kidney disease.

Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease

Dietary Lipids and Dyslipidemia in Chronic Kidney Disease

Activated NF-κB/Nrf2 and Wnt/β-catenin Pathways Are Associated with Lipid Metabolism in CKD Patients with Microalbuminuria and Macroalbuminuria

Characteristics of lipid abnormalities in patients with chronic kidney disease and current treatment

Risk prediction model of chronic kidney disease in health management population

Targeted Metabolomics Identified Novel Metabolites, Predominantly Phosphatidylcholines and Docosahexaenoic Acid-Containing Lipids, Predictive of Incident Chronic Kidney Disease in Middle-to-elderly-aged Chinese Adults

Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease

Oxidative Stress and Lipid Dysregulation in Lipid Droplets: A Connection to Chronic Kidney Disease Revealed in Human Kidney Cells

Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease

Proteomics of CKD progression in the chronic renal insufficiency cohort

Assessment and Risk Prediction of Chronic Kidney Disease and Kidney Fibrosis Using Non-Invasive Biomarkers

Metabolic Assessment in Non-Dialysis Patients with Chronic Kidney Disease

Klotho exerts protection in chronic kidney disease associated with regulating inflammatory response and lipid metabolism